Health-related quality of life in survivors of severe COVID-19 infection
Background Long-term effects of Coronavirus Disease 2019 (COVID-19) are increasingly recognized as having a significant impact on Health-Related Quality of Life (HRQoL). Understanding HRQoL status for each patient affected by long COVID-19 and its determinants may have a key role to prevent and treat this condition. Methods In this prospective observational study conducted in a large academic COVID-19 hospital in Rome, participants were contacted 2 years after hospital admission for severe COVID-19. To assess HRQoL, EQ-5D-5L and Visual analog scale (EQ VAS) standard questionnaires were administered by interview. Logistic regression model was used to the five health dimensions as dependent variables (0 = no problem, 1 = some/extreme problem). Key results In 137 enrolled patients, the mean pre-COVID and post-COVID EQ-5D-5L index and EQ-VAS score were 0.97 (SD 0.06), 0.79 (SD 0.26) and 72.38 (SD 15.18), respectively. After subdivision of the participants for clinical and social variables, the EQ-5D-5L index resulted significantly lower than in the pre-COVID-19 period. Female gender, unemployed status, and chronic comorbidities were the most common predictors for having any problems in each EQ-5D-5L domain, while also older age and higher Body Mass Index (BMI) showed to be related to a lower EQ-VAS score. Conclusion HRQoL showed to be still low in patients 2 years after acute severe COVID-19. Given the significant impact of SARS-CoV-2 on long-term chronic symptoms, predictors of poor outcomes must be considered during the acute phase of illness to plan a tailored follow-up path for each patient..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:74 |
---|---|
Enthalten in: |
Pharmacological reports - 74(2022), 6 vom: 14. Nov., Seite 1286-1295 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
d’Ettorre, Gabriele [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
COVID-19 |
---|
Anmerkungen: |
© The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
---|
doi: |
10.1007/s43440-022-00433-5 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR048826448 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR048826448 | ||
003 | DE-627 | ||
005 | 20230519110905.0 | ||
007 | cr uuu---uuuuu | ||
008 | 221207s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s43440-022-00433-5 |2 doi | |
035 | |a (DE-627)SPR048826448 | ||
035 | |a (SPR)s43440-022-00433-5-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a d’Ettorre, Gabriele |e verfasserin |4 aut | |
245 | 1 | 0 | |a Health-related quality of life in survivors of severe COVID-19 infection |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
520 | |a Background Long-term effects of Coronavirus Disease 2019 (COVID-19) are increasingly recognized as having a significant impact on Health-Related Quality of Life (HRQoL). Understanding HRQoL status for each patient affected by long COVID-19 and its determinants may have a key role to prevent and treat this condition. Methods In this prospective observational study conducted in a large academic COVID-19 hospital in Rome, participants were contacted 2 years after hospital admission for severe COVID-19. To assess HRQoL, EQ-5D-5L and Visual analog scale (EQ VAS) standard questionnaires were administered by interview. Logistic regression model was used to the five health dimensions as dependent variables (0 = no problem, 1 = some/extreme problem). Key results In 137 enrolled patients, the mean pre-COVID and post-COVID EQ-5D-5L index and EQ-VAS score were 0.97 (SD 0.06), 0.79 (SD 0.26) and 72.38 (SD 15.18), respectively. After subdivision of the participants for clinical and social variables, the EQ-5D-5L index resulted significantly lower than in the pre-COVID-19 period. Female gender, unemployed status, and chronic comorbidities were the most common predictors for having any problems in each EQ-5D-5L domain, while also older age and higher Body Mass Index (BMI) showed to be related to a lower EQ-VAS score. Conclusion HRQoL showed to be still low in patients 2 years after acute severe COVID-19. Given the significant impact of SARS-CoV-2 on long-term chronic symptoms, predictors of poor outcomes must be considered during the acute phase of illness to plan a tailored follow-up path for each patient. | ||
650 | 4 | |a Quality of life |7 (dpeaa)DE-He213 | |
650 | 4 | |a Health-related quality of life |7 (dpeaa)DE-He213 | |
650 | 4 | |a HRQoL |7 (dpeaa)DE-He213 | |
650 | 4 | |a SARS-CoV2 |7 (dpeaa)DE-He213 | |
650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
650 | 4 | |a Post-COVID |7 (dpeaa)DE-He213 | |
700 | 1 | |a Vassalini, Paolo |4 aut | |
700 | 1 | |a Coppolelli, Vincenzo |4 aut | |
700 | 1 | |a Gentilini Cacciola, Elio |4 aut | |
700 | 1 | |a Sanitinelli, Letizia |4 aut | |
700 | 1 | |a Maddaloni, Luca |4 aut | |
700 | 1 | |a Fabris, Silvia |4 aut | |
700 | 1 | |a Mastroianni, Claudio M. |4 aut | |
700 | 1 | |a d’Ettorre, Gabriella |4 aut | |
700 | 1 | |a Ceccarelli, Giancarlo |0 (orcid)0000-0001-5921-3180 |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Pharmacological reports |d Heidelberg : Springer Nature, 1998 |g 74(2022), 6 vom: 14. Nov., Seite 1286-1295 |w (DE-627)SPR038875861 |w (DE-600)2129019-2 |x 2299-5684 |7 nnns |
773 | 1 | 8 | |g volume:74 |g year:2022 |g number:6 |g day:14 |g month:11 |g pages:1286-1295 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s43440-022-00433-5 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 74 |j 2022 |e 6 |b 14 |c 11 |h 1286-1295 |